Heliosonix is an imaging solutions company for preclinical and clinical applications. Their optoacoustic imaging technology has been validated with 11 customers.

Heliosonix generates revenue with their animal research product: 2 deliveries in 2020 and a robust sales funnel. Their clinical products include cancer and stroke diagnostics and image-guided interventions with TAM $10B+: They have multiple shots on goal to launch a $1B+ product. The first FDA approval targeted in 2021. The Heliosonix team consists of MedTech veterans of Medtronic and J&J, and their technical founder is recognized as the father of biomedical optoacoustic imaging.

7707 Fannin Street #200
Houston, TX 77054
United States